Gilead Sciences, Inc. (GILD): Price and Financial Metrics
Gilead Sciences, Inc. (GILD)
Today's Latest Price: $73.51 USD
Updated Apr 9 12:00am
Add GILD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GILD Stock Summary
- With a market capitalization of $93,458,567,078, Gilead Sciences Inc has a greater market value than 98.57% of US stocks.
- Of note is the ratio of Gilead Sciences Inc's sales and general administrative expense to its total operating expenses; merely 17.09% of US stocks have a lower such ratio.
- The volatility of Gilead Sciences Inc's share price is greater than that of only 1.86% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Gilead Sciences Inc, a group of peers worth examining would be ASML, ABBV, TXN, BMY, and QCOM.
- Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to www.gilead.com.
GILD Stock Price Chart More Charts
GILD Price/Volume Stats
| Current price | $73.51 | 52-week high | $85.97 |
| Prev. close | $74.99 | 52-week low | $60.89 |
| Day low | $72.95 | Volume | 12,821,000 |
| Day high | $74.60 | Avg. volume | 19,420,191 |
| 50-day MA | $71.81 | Dividend yield | 3.7% |
| 200-day MA | $66.83 | Market Cap | 92.55B |
Gilead Sciences, Inc. (GILD) Company Bio
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $73.51 | $74.96 | 2% |
We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 45th percentile in terms of potential gain offered. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:
- Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
- The weighted average cost of capital for the company is 7. This value is greater than just 14.08% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 0% |
| 1% | 1% |
| 2% | 2% |
| 3% | 3% |
| 4% | 4% |
| 5% | 5% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GILD, try ICLR, NHC, REGN, ADMT, and SYNH.
Top Stories View All
Best & Worst Performing Stock Industries for April 9, 2020
Best & Worst Performing Small Cap Stocks for April 9, 2020
Best & Worst Performing Mid Cap Stocks for April 9, 2020
Best & Worst Performing Large Cap Stocks for April 9, 2020
Best & Worst Performing Mega Cap Stocks for April 9, 2020
View All Top Stories
Loading social stream, please wait...